ibusinesslines.com July 23, 2018

Synergy Pharmaceuticals Inc 174% Potential Upside Now Implied by Rodman & Renshaw

25 January 2017, 08:48 | Kelvin Horton

Synergy Pharmaceuticals Inc 174% Potential Upside Now Implied by Rodman & Renshaw

Synergy Pharmaceuticals Inc 174% Potential Upside Now Implied by Rodman & Renshaw

According to consensus agreement of 6 analysts Synergy Pharmaceuticals Inc (NASDAQ: SGYP) will report earnings per share of $-0.2 in their quarterly report and it is expected to announce the company's results on 2/23/17. BlackRock Fund Advisors now owns 8,824,549 shares of the biopharmaceutical company's stock valued at $33,533,000 after buying an additional 3,120,748 shares during the last quarter.

If we look at the Volatility of the company, Week Volatility is 6.69%, whereas Month Volatility is at 6.15%. Currently, 15.3% of the shares of the company are sold short.

Executives hold 0.39 percent of the stock. Victory Capital, an Ohio-based fund reported 3,651 shares.

Biogen Inc. (NASDAQ: BIIB) [Trend Analysis] retains strong position in active trade, as shares scoring 0.11% to $280.66 in active trade session, while looking at the shares volume, around 1.97 Million shares have changed hands in this session. D E Shaw And Company holds 0% or 188,211 shares in its portfolio. Canaccord Genuity restated a "buy" rating and issued a $13.00 price objective on shares of Synergy Pharmaceuticals in a research report on Friday, October 21st. Dividends are mostly given in terms of cash payments, property or as shares of stock. The company has 0.80% insider ownership. Blackrock Japan Communication Ltd accumulated 644 shares or 0% of the stock.

05/12/2015 - Synergy Pharmaceuticals, Inc. was upgraded to " by analysts at Zacks.

Insider Transactions: Since September 16, 2016, the stock had 0 insider buys, and 4 sales for $20.41 million net activity. BRANCACCIO JOHN P had sold 2,518 shares worth $14,504 on Monday, September 19.

10/24/2016 - Synergy Pharmaceuticals, Inc. had its " rating reiterated by analysts at H.C. Wainwright. After $-0.22 actual EPS reported by Synergy Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -22.73% EPS growth.

Synergy Pharmaceuticals, Inc. (NASDAQ: SGYP) has its dividend (annual) of 0 while its Dividend Yield (annual) is 0%.

Trulance met the main goals of two late-stage studies in December on irritable bowel syndrome patients with constipation (IBS-C). "Synergy Pharmaceuticals, Inc.is headquartered in New York, New York". Large ranges indicate high volatility and small ranges indicate low volatility. Current price places the company's stock 28.95% away from its 200-day simple moving average, 5.13%, away from the 50-day average and also -4.19% away from 20-day average. Swiss National Bank increased its stake in shares of Synergy Pharmaceuticals by 67.8% in the third quarter. Rodman & Renshaw maintained Synergy Pharmaceuticals Inc (NASDAQ: SGYP) rating on Friday, December 23. It has been assigned a low target price of $6.5 and a high target price of $18. The firm has " rating given on Thursday, October 29 by Roth Capital. (NASDAQ: SGYP) now has a Mean Price Target of $11.5. Higgins has a 32.4% average return when recommending SGYP, and is ranked #4247 out of 4361 analysts.

SGYP has been the subject of several recent research reports. (NASDAQ: SGYP) was down -7.80% during the last trading session, with a day high of 6.71. Analysts mean target price for Twilio Inc. The firm earned "Outperform" rating on Thursday, January 5 by Oppenheimer.

In Synergy Pharmaceuticals Inc. TRULANCE is the first drug created to replicate the function of uroguanylin, a naturally occurring and endogenous human gastrointestinal (GI) peptide that is thought to stimulate fluid secretion which results in a stool consistency associated with more regular bowel function.

Other News

Trending Now

Starving bears at Indonesia's 'death zoo' spark outrage
During a follow-up visit this month, they found there were still "dirty enclosures" and bears "looking hungry", the group said. Many of Indonesia's zoos are poorly maintained and there are regular reports of animals dying in captivity.

Dont Miss